Vicarious Surgical (NYSE:RBOT) announced today that it appointed Stephen From as CEO, effective Aug. 7, 2025.
Adam Sachs, current CEO, co-founder and board member, plans to remain with the company. He stays on as president, co-founder and board member in an operational capacity as a member of the company’s leadership team.
Sachs has led the Waltham, Massachusetts-based surgical robotics maker since co-founding it in 2014. The company develops a robotic platform designed to increase the efficiency of surgical procedures. Vicarious hopes to improve patient outcomes and reduce healthcare costs. Through a novel approach, the Version 1.0 (V1.0) system uses proprietary, human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery.
The company previously set its sights on first-in-human trials midway through this year. However, it pushed V1.0’s timeline back in November 2023. In March 2024, the company maintained its timeline to have V1.0 ready for an FDA submission by early- to mid-fiscal 2026.
Last fall, the company said it planned for a year-end cadaver lab for V1.0, followed by efforts toward verification, validation, and optimization of the system ahead of formal clinical testing. In May, Vicarious announced a new hospital collaboration, moving closer to bringing its surgical robot technology to patients.
“It has been an incredible journey to lead Vicarious Surgical from its inception through pre-clinical testing, and I’m proud of all we’ve accomplished to date. As I transition into the role of president, I’m excited to welcome Stephen as our new CEO,” said Sachs. “I believe his leadership and experience are exactly what we need at this pivotal stage, and I look forward to working closely with him to advance our mission of transforming surgical care through innovative robotics.”
More about new Vicarious Surgical CEO Stephen From
From brings more than 20 years of leadership in the healthcare and financial industry. Most recently, he served as CEO of Aruna Bio. From 2005 to 2021, he served as president and CEO, then from February 2021 to January 2022, he served as executive chair of Kiora Pharmaceuticals. He led Kiora through its IPO and multiple acquisitions and licensing transactions.
Before EyeGate, From served as CFO of Centelion SAS, then a biotech subsidiary of Sanofi-Aventis. He also spent several years in investment banking, working in the life sciences sector at Bank of America Securities and Robertson Stephens.
“I am honored to join the Vicarious Surgical team at this pivotal time in its evolution. The company’s technology offers a significant advancement from today’s surgical approaches with the potential to transform modern surgery and improve outcomes for patients worldwide,” said From. “I look forward to working alongside this talented team and board to advance our strategic priorities and deliver on the promise of this innovative platform.”
